James Love and James K. Glassman, Don’t Kill Competition for High-Tech Drugs, Roll Call, Sept. 9, 2009.
KEI Statement on Eshoo/Barton amendment
Some reporting
In May 2009, at the WIPO Standing Committee on Copyright and Related Rights (SCCR) 18th session, the governments of Brazil, Ecuador and Paraguay formally tabled a proposal to WIPO endorsing the World Blind Union’s Treaty for Reading Disabled Persons.
In an August 14, 2009 article in the LA Times, Tom Hamburger provides yet another installment in the ongoing disclosures about a secret White House deal with PhRMA on pharmaceutical pricing.
At KEI Washington, DC offices.
When: Tuesday June 30, 2009
Time: 12:30-2:00pm
Location:
Knowledge Ecology International (KEI)
1621 Connecticut Ave NW, Suite 500
Washington, DC 20009
Tel +1 202 332 2670
Matthew Flynn, a doctoral candidate in Sociology at the University of
Texas at Austin, will be presenting some of his dissertation research on
Brazilian pharmaceutical policies. The topics include Brazil’s use of
compulsory licenses, the Bolar Exception, and production of
anti-retrovirals in public laboratories. Matthew holds a Masters of
Continue Reading
The rollcall for the biosimilars vote in on the Internet here. Based upon the count released by the committee, voting for the Eshoo Amendment were 26 Democrats and 21 Republicans. Voting against were 1 republican (Deal) and 10 Democrats. One Republican did not vote. I have bolded the Nay votes.
By James Love, on July 31st, 2009
On Thursday, July 30, 2009, the White House office of the United States Trade Representative denied release of 4 new proposals for text that were circulated in July to “all countries” in the Anti-Counterfeiting Trade Agreement (ACTA) negotiations. The request was limited to documents that were prepared in the past 90 days for purpose of discussion at the July 2009 ACTA negotiating meeting held in Morocco.
USTR located 4 such documents, but denied the FOIA request under 5 USC 552(b)(1). The specific exception cited reads as follows:
The Obama Administration, with the support of a Democrat-controlled U.S. Congress, is insisting the Anti-Counterfeiting Trade Agreement (ACTA) negotiations be conducted in secret. We know, from documents obtained in Europe and the summaries released in April 2009, that the draft ACTA has sections that deal with both injunctions and damages. We don’t have the current text. Continue Reading
As candidates, almost all democrats have promised voters, in several elections, they will support parallel trade in pharmaceuticals from Canada and other high income countries. As elected officials, nothing happens. President Obama already has authority to permit imports of medicines, if he wanted to exercise it. But not only is the White House not fullfillinbg the promise to allow imports, it has promised the CEO of PhRMA and several big companies that they won’t allow parallel trade in the health reform bill.